<DOC>
	<DOCNO>NCT00696475</DOCNO>
	<brief_summary>Hypertriglyceridemia affect 30 % population US . Very high level triglyceride know risk factor pancreatitis . In addition , study show hypertriglyceridemia independent risk factor cardiovascular disease . Diazoxide KATP channel opener . It approve FDA oral suspension treatment hyperinsulinemic hypoglycemic condition IV solution malignant hypertension . Preclinical clinical study suggest diazoxide potential therapeutic agent hypertriglyceridemia . Diazoxide choline novel , highly crystalline proprietary salt diazoxide , formulate controlled-release tablet suitable per day dosing . This current study design assess effect diazoxide choline triglycerides subject baseline hypertriglyceridemia . In addition , effect lipid parameter , glucose insulin , body weight well safety tolerability diazoxide choline assess .</brief_summary>
	<brief_title>Diazoxide Choline Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>triglyceride ≥ 250 mg/dL &lt; 600 mg/dL BMI 18.5 45 Signed inform consent form Fasting glucose ≥ 126 mg/dL Glycosylated hemoglobin ( HbA1c ) &gt; 6.5 % LDL cholesterol &gt; 190 mg/dL Known history type I II DM Known history type I III hyperlipidemia Weight change &gt; 3 kg screen baseline visit Pregnancy intention become pregnant Presence significant underlying condition may interfere assessment study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>